Defining Success in IBD: Treat-to-Target
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Revisiting Anti-TNFs: Role, Risks, and Real-World Considerations
Michael Dolinger, MD, MBA
David T. Rubin, MD
Targeting IL-23 Pathways: Evolving Biologic Strategies in IBD
The Future of Biologic Treatment in IBD: What’s on the Horizon
Setting the Stage: Why Rethinking IBD Care Matters Now
Small Molecules in IBD: JAK Inhibitors and S1P Modulators
Putting It All Together: A Practical IBD Treatment Selection Primer
IBD Beyond Symptoms: What Community GIs Need to Know
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
Pathophysiology of IBD: The War Within
Beyond Biology: Environmental and Lifestyle Influences in IBD
Tailoring Treatment: Can You Select the Best Therapy?
David Rubin, MD
Brooke Hodnick, PA-C, MPAS
Remission: Can You Prove It?
Kimberly D. Orleck, PA-C
Treat-to-Target: Are We There Yet?
Jennifer Geremia, PA-C
Case Review: Can You Crack This IBD Case?
Loading...
We're glad to see you're enjoying Crohn's Colitis Professional… but how about a more personalized experience?
Press cancel to remain on Crohn's Colitis Professional. Press the link below or the continue button to keep going.